BioSyent (CVE:RX) Stock Price Crosses Above 50 Day Moving Average - Should You Sell?

Key Points

• BioSyent Inc. shares have surpassed their fifty-day moving average, trading at C$12.04 compared to the fifty-day average of C$11.65.
• The company announced a quarterly dividend of $0.05 per share, translating to a 1.7% yield and an annualized dividend of $0.20.
• BioSyent has a market capitalization of C$135.53 million and a price-to-earnings ratio of 16.95, indicating potential growth for investors.

BioSyent Inc. (CVE:RX - Get Free Report)'s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$11.65 and traded as high as C$12.04. BioSyent shares last traded at C$12.04, with a volume of 2,600 shares.

BioSyent Stock Down 1.7%

The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of C$133.22 million, a PE ratio of 16.66 and a beta of 0.49. The firm has a 50-day moving average of C$11.65 and a two-hundred day moving average of C$11.31.

BioSyent Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 1.7%. BioSyent's payout ratio is 26.76%.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.